The Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, was awarded a $452,544 federal Project Grant (R21CA280643) from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to develop a novel therapeutic strategy for combating the suppressive effects of regulatory T cells (Tregs) in the solid tumor microenvironment. The research aims to inhibit the signaling of the metabolite succinate, which promotes the induction and immunosuppressive phenotype of Tregs, in order to enhance the anti-tumor response of tumor-specific CD8+ T cells. The project will utilize genetically modified tumor models, small molecule inhibitors, and a humanized mouse model to comprehensively assess the role of succinate signaling in Treg-mediated immunosuppression and develop an innovative approach to improve the efficacy of T cell-based immunotherapies for solid tumors. The award period runs from July 1, 2024 to June 30, 2026.
Generated 2/25/25, 4:36 AM